Pulse Biosciences (NASDAQ:PLSE) Share Price Crosses Below 50-Day Moving Average – What’s Next?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $19.37 and traded as low as $17.66. Pulse Biosciences shares last traded at $17.87, with a volume of 196,194 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Thursday, January 2nd.

Pulse Biosciences Price Performance

The firm has a fifty day moving average of $19.37 and a 200 day moving average of $18.47.

Insider Transactions at Pulse Biosciences

In related news, CEO Burke Thomas Barrett sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the sale, the chief executive officer now owns 63,172 shares in the company, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert W. Duggan bought 55,256 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were bought at an average price of $17.18 per share, with a total value of $949,298.08. Following the completion of the purchase, the director now owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 71.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Pulse Biosciences in the 3rd quarter worth approximately $588,000. Charles Schwab Investment Management Inc. increased its holdings in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after buying an additional 97,565 shares during the last quarter. State Street Corp raised its position in Pulse Biosciences by 17.8% in the third quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after acquiring an additional 69,696 shares during the period. Geode Capital Management LLC raised its position in Pulse Biosciences by 7.8% in the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after acquiring an additional 33,200 shares during the period. Finally, Franklin Resources Inc. purchased a new position in shares of Pulse Biosciences during the 3rd quarter worth $378,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.